Reviewing Seattle Genetics Inc. (SGEN)’s and Altimmune Inc. (NASDAQ:ALT)’s results

This is therefore a comparing of the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation in Seattle Genetics Inc. (NASDAQ:SGEN) and Altimmune Inc. (NASDAQ:ALT). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Seattle Genetics Inc. 654.70M 18.20 222.69M -1.44 0.00
Altimmune Inc. 10.55M 1.77 28.83M -38.81 0.00

Demonstrates Seattle Genetics Inc. and Altimmune Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 has Seattle Genetics Inc. and Altimmune Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Seattle Genetics Inc. -34.01% -16.8% -14.5%
Altimmune Inc. -273.27% -74.2% -50.4%

Risk & Volatility

Seattle Genetics Inc. has a 2.3 beta, while its volatility is 130.00% which is more volatile than Standard and Poor’s 500. Competitively, Altimmune Inc.’s 241.00% volatility makes it more volatile than Standard and Poor’s 500, because of the 3.41 beta.

Liquidity

Seattle Genetics Inc. has a Current Ratio of 2.9 and a Quick Ratio of 2.7. Competitively, Altimmune Inc.’s Current Ratio is 1.4 and has 1.4 Quick Ratio. Seattle Genetics Inc.’s better ability to pay short and long-term obligations than Altimmune Inc.

Analyst Ratings

The following table shown below contains the ratings and recommendations for Seattle Genetics Inc. and Altimmune Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Seattle Genetics Inc. 0 1 3 2.75
Altimmune Inc. 0 0 0 0.00

Seattle Genetics Inc.’s average price target is $86, while its potential upside is 15.86%.

Insider and Institutional Ownership

The shares of both Seattle Genetics Inc. and Altimmune Inc. are owned by institutional investors at 0% and 11% respectively. About 0.9% of Seattle Genetics Inc.’s share are held by insiders. On the other hand, insiders held about 3.7% of Altimmune Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Seattle Genetics Inc. -0.98% -5.81% 17.34% -5.7% 37.73% 27.06%
Altimmune Inc. -3.97% -16.61% -19.64% -71.4% -94.39% 29.13%

For the past year Seattle Genetics Inc. was less bullish than Altimmune Inc.

Summary

On 9 of the 11 factors Seattle Genetics Inc. beats Altimmune Inc.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML); ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL. In addition, it is involved in developing SEA-CD40 that is in Phase I clinical trial for patients with solid tumors and hematologic malignancies; SGN-CD19B, which is in Phase I clinical trial ongoing for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; SGN-CD123A that is in Phase I trial for patients with relapsed or refractory AML; SGN-CD352A, which is in Phase I clinical trial for patients with relapsed or refractory multiple myeloma; SGN-2FF that is in Phase I clinical trial for patients with advanced solid tumors; and ASG-15ME that is in Phase I clinical trial for patients with urothelial cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; and Unum Therapeutics, Inc., as well as has co-development agreement with Agensys, Inc. and Genmab A/S. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, designs and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. Its preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others. The company was formerly known as Vaxin Inc. Altimmune, Inc. was founded in 1997 and is based in Gaithersburg, Maryland.

"

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.